Plasma Fractionation: Strengthening the Future of Plasma-Derived Medicines

 

The global healthcare landscape is evolving rapidly, with rare chronic diseases and immune-related disorders emerging as critical areas of concern. At the heart of many advanced therapies addressing these conditions lies plasma fractionation a highly specialized process that transforms human blood plasma into essential, life-saving medicines. According to industry estimates, the global plasma fractionation market was valued at US$ 24.1 billion in 2022 and is projected to reach US$ 42.6 billion by 2031, expanding at a CAGR of 6.7% from 2023 to 2031. This steady growth reflects rising medical need, scientific progress, and expanding plasma collection infrastructure worldwide.

 

Understanding Plasma Fractionation and Its Medical Importance

Plasma fractionation is the large-scale process of separating plasma into its key protein components, such as immunoglobulins, albumin, and coagulation factors. These proteins form the backbone of therapies used to treat a wide range of conditions, including hemophilia, immunodeficiency disorders, autoimmune diseases, neurological conditions, and critical care complications.

What makes plasma fractionation particularly valuable is its efficiency: multiple therapeutic products can be derived from a single plasma donation. This not only maximizes the utility of donated plasma but also ensures a consistent supply of high-purity, clinically safe products that are indispensable in modern medicine.

In recent years, the industry has placed strong emphasis on product safety, traceability, and premium quality, supported by advancements in biotechnology, purification techniques, and regulatory oversight.

 

Analyst Viewpoint: Rare Diseases Driving Market Momentum

One of the most significant drivers of plasma fractionation market growth is the rising prevalence of rare chronic and genetic diseases. Improvements in genetic testing and diagnostic technologies have made it easier to identify such conditions, which were often underdiagnosed in previous decades.

Diseases such as hemophilia, hereditary angioedema, and primary immunodeficiency disorders rely heavily on plasma-derived therapies for long-term management. According to Global Genes, more than 400 million people globally are affected by one of over 10,000 known rare genetic disorders, with nearly 50% of patients being children. Alarmingly, it can take up to five years on average to receive an accurate diagnosis—underscoring the need for accessible, effective therapies once diagnosis is confirmed.

As awareness improves and diagnosis rates increase, demand for plasma-derived medicines continues to rise, directly fueling growth in the plasma fractionation industry.

 

Get Sample PDF Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=48600

 

Rising Demand for Plasma Proteins

Another critical growth factor is the increasing global demand for plasma proteins, driven in part by an aging population. Older adults are more susceptible to immune deficiencies, liver disorders, neurological diseases, and critical care needs—all of which often require plasma-based treatments.

Plasma-derived therapies are also gaining traction in cell therapy and regenerative medicine, opening new therapeutic frontiers. According to the Plasma Protein Therapeutics Association (PPTA), 8.4 million liters of plasma were collected in the European Union alone in 2021 to manufacture plasma-derived therapies.

To meet this demand, governments and private organizations are investing heavily in plasma collection infrastructure. The U.S. currently has around 740 plasma collection centers, while Europe hosts approximately 111 centers, supported by initiatives from organizations such as the European Blood Alliance.

 

Regional Outlook: North America Leads the Market

North America dominated the plasma fractionation market in 2022, supported by advanced healthcare infrastructure, strong R&D capabilities, and high awareness of rare disease treatments. In the United States alone, nearly 30 million people are affected by rare genetic diseases—roughly one in every ten individuals, according to Rare Genomics.

Europe represents another key growth region, with steady expansion expected through 2031. Supportive government policies, rising investment in personalized medicine, and a strong focus on genetic disorder treatment are driving demand. The European Commission estimates that over 30 million people in the EU live with genetic conditions, including around 6,000 documented rare diseases.

 

Competitive Landscape and Key Players

The plasma fractionation market is moderately consolidated, with leading players investing heavily in capacity expansion, advanced fractionation technologies, and global plasma collection networks. Major companies operating in the global market include:

• CSL Limited
• Takeda Pharmaceutical Company
• GRIFOLS
• Baxter International Inc.
• Octapharma AG
• Kedrion
• Biotest AG
• Sanquin
• Taibang Biological Group Co., Ltd

These companies are evaluated based on their product portfolios, geographic presence, financial performance, and long-term business strategies.

 

Key Industry Developments

Recent developments highlight the industry’s commitment to capacity expansion and emerging markets:

• December 2023: GC Biopharma announced plans to establish the largest plasma fractionation facility in Indonesia, with a capacity of 400,000 liters per year, expected to begin production in 2027.
• December 2023: PlasmaGen Biosciences raised US$ 27 million in equity financing to expand its plasma-derived product portfolio and manufacturing capabilities, particularly for emerging economies.

Such investments are expected to strengthen global supply chains and improve access to plasma-derived therapies in underserved regions.

 

Outlook Through 2031

Looking ahead, the plasma fractionation market is poised for sustained growth, supported by demographic shifts, expanding therapeutic applications, and continuous technological innovation. While challenges such as plasma supply constraints and complex regulatory requirements remain, ongoing investments in collection infrastructure, safety standards, and R&D are expected to mitigate these issues.

Overall, plasma fractionation will continue to play a vital role in modern healthcare, enabling effective treatment for rare, chronic, and life-threatening conditions—making it one of the most strategically important segments of the global biopharmaceutical industry through 2031 and beyond.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453